Revolutionising Cardiometabolic Care: Exploring, Innovating and Advancing Cardioprotection

Chairs: Alice Cheng (CAN), Mikael Rydén (SWE)

Part 1: Exploring the background of person-centred care across the spectrum of related cardiometabolic diseases​

09:00 – 09:15The Prologue: welcome and introductions

Alice Cheng (CAN)
Mikael Rydén (SWE)

09:15 – 09:35Chapter 1: Person-centred care – the evolving landscape and new horizons in obesity managementCarel le Roux (IRL)
09:35 – 09:55Chapter 2: Person-centred care – the need for treatment of cardiometabolic diseasesJohn Buse (USA)
09:55 – 10:10Chapter 3: Focus on PAD – synergistic strategies across ASCVDSubodh Verma (CAN)
10:10 – 10:25Chapter 4: Person-centred care – heart failure for people with CKM diseasesMichele Senni (ITA)
10:25 – 10:40Chapter 5: Summarising the evidence for person-centered care across cardiometabolic diseasesAll faculty
10:40 – 10:55Coffee break

Part 2: Focusing in on an expanding spectrum of cardiometabolic diseases and patient phenotypes

10:55 – 11:00Checking the contents page: welcome back

Alice Cheng (CAN)
Mikael Rydén (SWE)

11:00 – 11:15Chapter 6: Focus on kidneys – synergic strategies across the CKM continuumChristoph Wanner (DEU)
11:15 – 11:35Chapter 7: Focus on MASH – integrating emerging data into clinical pathwaysLaurent Castera (FRA)
11:35 – 11:50Chapter 8: Focus on childhood – charting new paths in obesity managementAntje Körner (DEU)
11:50 – 12:05Chapter 9: Summarising the focus and translating it into clinical practiceAll faculty
12:05 – 12:45Lunch

Part 3: Semaglutide and the path to holistic cardiometabolic disease care

12:45 – 12:50Checking the contents page: welcome back

Alice Cheng (CAN)
Mikael Rydén (SWE)

12:50 – 13:10Chapter 10: The prequel to semaglutide and the evidence that started the journeyAnna Secher (DNK)
13:10 – 13:35Chapter 11: The science of the cardiometabolic care – clinical evidence and perspectivesArya Sharma (DEU)
13:35 – 13:50Chapter 12: The voice of the patient – hearing their call to action for personalised careTBC
13:50 – 14:10Chapter 13: Summarising the journey and exploring the co-authors viewsAll faculty
14:10 – 14:25Coffee break

Part 4: The future chapters – advancing the management of cardiometabolic diseases

14:25 – 14:30Checking the contents page: welcome back

Alice Cheng (CAN)
Mikael Rydén (SWE)

14:30 – 14:45Chapter 14: Advancements in nutrient-stimulated hormone therapies: the evolution of amylinMatthias Blüher (DEU)
14:45 – 15:00Chapter 15: Advancements to clinical excellence in obesity through the potential of complementary biologiesTBC
15:00 – 15:15Chapter 16: Advancements across the metabolic disease continuum – expanding the evidenceMelanie Davies (GBR)
15:15 – 15:30Chapter 17: Advancements in the treatment toolbox – integrating amycretinAnia Jastreboff (USA)
15:30 – 15:50Chapter 18: Summarising the advancements and looking to a future of clinical excellenceAll faculty
15:50 – 16:05Coffee break

Part 5: Innovating our heritage – once-weekly basal insulin therapy

16:05 – 16:10Checking the contents page: welcome back

Alice Cheng (CAN)
Mikael Rydén (SWE)

16:10 – 16:30Chapter 19: Innovation in basal insulins – individualised treatment in focus

Athena Philis-Tsimikas (USA)
Harald Sourij (AUT)

16:30 – 16:45Chapter 20: Innovation in combination insulin therapy – benefits beyond glycaemic controlLinong Ji (CHN)
16:45 – 16:55Chapter 21: Summarising the innovation for people in need of insulinAll faculty
16:55 – 17:00The Epilogue: summary and close

Alice Cheng (CAN)
Mikael Rydén (SWE)

Novo Nordisk logo
  • Monday, 15 September 2025
  • 09:00 - 17:00 CEST
  • Vienna Hall

Legal notice | Data protection

5b3635c62fe85b4dfdb2a6c4_interplan_logo_1